Business Description
Xencor Inc
NAICS : 325412
SIC : 2834
ISIN : US98401F1057
Description
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.8 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.53 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.57 | |||||
| Beneish M-Score | -3.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.1 | |||||
| 3-Year EBITDA Growth Rate | -19.2 | |||||
| 3-Year EPS without NRI Growth Rate | -19.6 | |||||
| 3-Year Book Growth Rate | 3.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.1 | |||||
| 9-Day RSI | 54.62 | |||||
| 14-Day RSI | 57.05 | |||||
| 6-1 Month Momentum % | -20.64 | |||||
| 12-1 Month Momentum % | 8.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.92 | |||||
| Quick Ratio | 6.92 | |||||
| Cash Ratio | 6.35 | |||||
| Days Sales Outstanding | 64.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.8 | |||||
| Shareholder Yield % | -1.67 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -129.81 | |||||
| Net Margin % | -132.74 | |||||
| FCF Margin % | 16.08 | |||||
| ROE % | -27.77 | |||||
| ROA % | -21.02 | |||||
| ROIC % | -60.01 | |||||
| 3-Year ROIIC % | -32.49 | |||||
| ROC (Joel Greenblatt) % | -164.15 | |||||
| ROCE % | -22.9 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.8 | |||||
| PB Ratio | 2.35 | |||||
| Price-to-Tangible-Book | 2.44 | |||||
| Price-to-Free-Cash-Flow | 52.98 | |||||
| Price-to-Operating-Cash-Flow | 38 | |||||
| EV-to-EBIT | -6.1 | |||||
| EV-to-EBITDA | -6.56 | |||||
| EV-to-Revenue | 8.11 | |||||
| EV-to-Forward-Revenue | 3.59 | |||||
| EV-to-FCF | 46.11 | |||||
| Price-to-Projected-FCF | 5.58 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 4.54 | |||||
| Price-to-Net-Cash | 5.39 | |||||
| Earnings Yield (Greenblatt) % | -16.39 | |||||
| FCF Yield % | 1.56 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers